"Ranbaxy Resolves Criminal and Civil Charges Through Record Settlement"

by Skadden, Arps, Slate, Meagher & Flom LLP

Executive Summary

On May 13, 2013, generic drug manufacturer Ranbaxy USA Inc. (Ranbaxy), a subsidiary of Indian generic drug manufacturer Ranbaxy Laboratories Limited, pled guilty to seven felony charges as part of a global settlement pursuant to which Ranbaxy will pay a total of $500 million to resolve criminal and civil False Claims Act (FCA) liability.1 In pleading guilty, Ranbaxy admitted to manufacturing and distributing adulterated drugs made at two of Ranbaxy’s facilities in Ponta Sahib and Dewas, India, failing to file required reports with the U.S. Food and Drug Administration (FDA), and making material false statements to FDA. Ranbaxy Laboratories Limited’s press release following the settlement noted that the conduct at issue occurred several years ago and that Ranbaxy’s current management cooperated fully in the Department of Justice’s (DOJ) investigation. The settlement follows upon Ranbaxy’s 2012 Consent Decree of Permanent Injunction and represents the largest drug safety settlement to date with a generic drug manufacturer. The settlement also makes good on government threats to use criminal and civil enforcement tools, including the FCA, to address serious manufacturing violations.

Settling Entities Ranbaxy USA Inc. (US subsidiary); Ranbaxy Laboratories Limited (Indian parent company); Ranbaxy, Inc.; Ranbaxy Pharmaceuticals, Inc.; Ranbaxy Laboratories, Inc.; and Ohm Laboratories, Inc. (all subsidiaries of Ranbaxy Laboratories Limited named in the qui tam FCA complaint).
Government Entities Involved U.S. Attorney’s Office for the District of Maryland; DOJ Civil Division Consumer Protection and Commercial Litigation Branches; certain states and the District of Columbia (which will enter Medicaid State Settlement Agreements with Ranbaxy).
Criminal Charges Resolved One felony count of violating the Federal Food, Drug, and Cosmetic Act (FDCA) by introducing adulterated drugs into interstate commerce with the intent to defraud and mislead; two felony counts of violating the FDCA by failing to file required reports with the intent to defraud and mislead; and four felony counts of violating 18 U.S.C. § 1001 by knowingly making material false statements to FDA.
Products Involved Felony FDCA counts: Sotret (branded generic isotretinoin, used to treat severe recalcitrant nodular acne), gabapentin (used to treat epilepsy and nerve pain), and ciprofloxacin (broad-spectrum antibiotic); Felony false statements counts: Cefaclor; Cefadroxil; Amoxicillin; and Amoxicillin and Clavulanate Potassium (all antibiotics).
Monetary Settlement Breakdown Total criminal penalties — $150 million, consisting of a criminal fine of $130 million and forfeiture of $20 million; total civil penalties — $350 million, of which the federal government share is $231.8 million and $118.2 million will go to the states participating in the settlement.
Relevant Time Period Felony adulteration charge relates to conduct between January 1, 2005, and December 31, 2006; failure to file reports charges relate to conduct in 2003, 2004 and 2007; civil FCA claims relate to conduct between April 1, 2003, and September 16, 2010.
Relator Dinesh Thakur, director of Project & Information Management with Ranbaxy Laboratories Limited in Gurgaon, Haryana, India, from June 2003 until April 2005. According to his qui tam complaint, Thakur had responsibility for portfolio and product management and established a program management office that oversaw internal data created during the formulation and manufacturing of Ranbaxy’s drugs. Thakur filed his qui tam action in April 2007. Pursuant to the settlement agreement, Thakur will receive approximately $48.6 million from the federal share of the civil settlement.
Related Matters In January 2012, Ranbaxy Laboratories Limited, its senior vice president, head global quality, and its managing director, as well as Ranbaxy USA Inc. and its regional director for the Americas, entered a consent decree of permanent injunction with FDA, acting through the U.S. Attorney’s Office for the District of Maryland. Pursuant to the consent decree, Ranbaxy is enjoined from manufacturing drugs at the Ponta Sahib and Dewas facilities until the facilities have been brought into full compliance with Good Manufacturing Practices (GMP). The consent decree also comprises notable data integrity requirements, including an audit of pending applications, the implementation of new procedures and controls to ensure data integrity, and the withdrawal of applications found to reflect untrue statements of material fact or a pattern or practice of data irregularities. Ranbaxy also agreed to relinquish 180-day marketing exclusivity rights for three pending generic drug applications, and additional applications are at risk if the consent decree’s deadlines are not met.
Exclusion/Debarment Implications Ranbaxy’s felony pleas under the FDCA subject it to mandatory FDA debarment pursuant to 21 U.S.C. § 335(a)(1). Ranbaxy’s felony false statements pleas under 18 U.S.C. § 1001 subject it to mandatory exclusion from participation in federal health care programs, pursuant to 42 U.S.C. § 1320a-7(a)(3) (felony conviction relating to health care fraud). The import of this debarment and exclusion is unclear, as Ranbaxy was purchased by Daiichi Sankyo Company, Limited in June 2008.

Allegations and Resolution

The Ranbaxy settlement resolves allegations that fall into three general categories, and are detailed in an Agreed Statement of Facts: (1) violating the FDCA by manufacturing and distributing drugs deemed adulterated because they were not manufactured in compliance with GMP; (2) violating the FDCA by failing to file required reports with FDA; and (3) making material false statements to FDA in annual reports. The felony adulteration count is based on FDA’s documentation of GMP violations during inspections of the Ponta Sahib facility in February 2006 and the Dewas facility in February to March 2006 and January to February 2008.

Ranbaxy has further admitted significant discrepancies in stability testing at both facilities. In particular, Ranbaxy admitted that it conducted stability testing several weeks or months later than the dates that were reported to FDA in annual reports and also conducted stability tests that were required to be conducted at specified intervals (e.g., three, six and nine months) on the same day. Ranbaxy also admitted to storing stability samples pending testing in a four-degree Celsius refrigerator rather than a stability chamber. This practice was not disclosed to FDA; instead, Ranbaxy represented to FDA that its stability testing program was being conducted in compliance with protocols submitted to FDA. Significantly, Ranbaxy admitted that its GMP and stability testing deviations were identified in 2003 and 2005 by outside consultants hired to audit its manufacturing operations.

These stability testing deviations form the basis for Ranbaxy’s felony pleas to failing to timely file required reports and making material false statements to FDA. In particular, Ranbaxy admitted that it failed, as required under 21 U.S.C. § 314.81(b)(1), to submit a “field alert report” within three working days after receiving information concerning any bacteriological contamination, significant chemical, physical, or other change or deterioration, or failure to meet a specification established in an Abbreviated New Drug Application, of a distributed drug product. Ranbaxy further admitted that it made materially false statements to FDA regarding its stability testing program in annual reports filed in 2006 and 2007.

The settlement also resolves the allegations levied in the qui tam civil FCA action, United States ex rel. Thakur v. Ranbaxy Laboratories Limited, Civ. No. 1:07-cv-00962-JFM (D.Md.). In addition to alleging widespread GMP violations, the February 2010 amended complaint in that matter alleges that, with the knowledge and approval of senior management in India and the United States, Ranbaxy filed marketing applications for its generic antiretroviral drugs that were not supported by formulation, bioequivalence and/or stability data, or were supported by falsified data. The civil settlement agreement ultimately resolves allegations that Ranbaxy knowingly caused the submission of false claims by manufacturing, distributing and selling drugs whose strength, purity or quality differed from their specifications or were not manufactured according to the FDA-approved formulations.


The Ranbaxy settlement is significant in a number of respects. First, the $500 million total financial settlement represents the largest drug safety-related settlement with a generic manufacturer to date, and the seven felony guilty pleas are indicative of the severity of the allegations resolved. Second, the settlement has broader implications for DOJ and FDA enforcement trends: It makes good on repeated threats that the government intends to focus on manufacturing issues in addition to the advertising and promotion claims that have historically dominated drug and device manufacturer government investigations and settlements. Third, while there are strong legal arguments to the contrary, the settlement reflects DOJ’s belief that manufacturing and safety violations may be actionable under the civil False Claims Act.

However, the terms of the settlement provide only limited guidance for practitioners. Ranbaxy and the government agreed that Ranbaxy’s pecuniary gain from the criminal conduct was $100 million and that its gross gains were in excess of $100 million. Accordingly, the agreed upon criminal fine of $130 million is at the low end of the range determined by application of federal sentencing rules. However, Ranbaxy and the government did not stipulate as to the amount of the false claims that had been paid by the government for purchases of adulterated generic drugs. It is impossible, therefore, to determine the multiplier (from losses) that the government and Ranbaxy agreed to use to calculate the civil settlement of $350 million.

1 The information set forth herein is derived from publicly available sources.

Download PDF

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Skadden, Arps, Slate, Meagher & Flom LLP | Attorney Advertising

Written by:

Skadden, Arps, Slate, Meagher & Flom LLP

Skadden, Arps, Slate, Meagher & Flom LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.